Literature DB >> 28925369

Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN.

Sylvia Merkert1, Christien Bednarski2, Gudrun Göhring3, Toni Cathomen2, Ulrich Martin4.   

Abstract

Cystic fibrosis (CF) is a monogenetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which affects multiple organs. Human induced pluripotent stem cells (iPSCs) derived from CF patients and the generation of isogeneic gene-corrected control cell lines enable disease modelling, drug discovery or toxicological studies and therefore the development of CF patient-specific therapies. We have previously generated a hiPSC line from a CF patient homozygous for the p.Phe508del mutation. Here we used TALENs and single-stranded oligonucleotides to correct the mutated triplet in our CF-iPSC line.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28925369     DOI: 10.1016/j.scr.2017.07.010

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  9 in total

1.  Highly Efficient Gene Editing of Cystic Fibrosis Patient-Derived Airway Basal Cells Results in Functional CFTR Correction.

Authors:  Shingo Suzuki; Ana M Crane; Varada Anirudhan; Cristina Barillà; Nadine Matthias; Scott H Randell; Andras Rab; Eric J Sorscher; Jenny L Kerschner; Shiyi Yin; Ann Harris; Matthew Mendel; Kenneth Kim; Lei Zhang; Anthony Conway; Brian R Davis
Journal:  Mol Ther       Date:  2020-04-29       Impact factor: 11.454

2.  Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.

Authors:  Nicholas E King; Shingo Suzuki; Cristina Barillà; Finn J Hawkins; Scott H Randell; Susan D Reynolds; Barry R Stripp; Brian R Davis
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

Review 3.  Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks.

Authors:  Ulrich Martin
Journal:  Front Med (Lausanne)       Date:  2017-12-14

Review 4.  Gene and Base Editing as a Therapeutic Option for Cystic Fibrosis-Learning from Other Diseases.

Authors:  Karen Mention; Lúcia Santos; Patrick T Harrison
Journal:  Genes (Basel)       Date:  2019-05-21       Impact factor: 4.096

Review 5.  Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis.

Authors:  Iram Haq; Maryam Almulhem; Simone Soars; David Poulton; Malcolm Brodlie
Journal:  Pharmgenomics Pers Med       Date:  2022-02-05

Review 6.  Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis.

Authors:  Iris A L Silva; Onofrio Laselva; Miquéias Lopes-Pacheco
Journal:  J Pers Med       Date:  2022-08-16

Review 7.  The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology.

Authors:  Marta Stolarczyk; Bob J Scholte
Journal:  Mediators Inflamm       Date:  2018-01-09       Impact factor: 4.711

8.  P.F508del editing in cells from cystic fibrosis patients.

Authors:  Svetlana A Smirnikhina; Ekaterina V Kondrateva; Elmira P Adilgereeva; Arina A Anuchina; Milyausha I Zaynitdinova; Yana S Slesarenko; Angelina S Ershova; Kirill D Ustinov; Matvei I Yasinovsky; Elena L Amelina; Ekaterina S Voronina; Valentina D Yakushina; Vyacheslav Yu Tabakov; Alexander V Lavrov
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

Review 9.  Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis.

Authors:  Madalena C Pinto; Iris A L Silva; Miquéias Lopes-Pacheco; Miriam F Figueira; Margarida D Amaral
Journal:  J Exp Pharmacol       Date:  2021-07-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.